Compare Mesoblast Limited (MESO) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Palantir Technologies Inc — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.16B), while Palantir Technologies Inc trades at $172.89 (market cap $421.09B). The key difference: Palantir Technologies Inc is far larger — about 194.9× Mesoblast Limited's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | PLTR | |
|---|---|---|
Market Cap | $2.16B | $421.09B |
Sector | Technology | Technology |
52-Week High | $20.96 | $207.18 |
52-Week Low | $12.88 | $107.27 |
Enterprise Value | $2.17B | $411.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Palantir (PLTR) trades at $172.01, up 10.32% in 24 hours and near its 52-week high, with bullish technical signals from moving averages. The company reported strong Q2 2026 earnings, beating estimates with 93% revenue growth and a 55% net income margin, while raising full-year guidance. Analyst consensus is a Buy with a $213.44 price target, reflecting optimism around AI-driven commercial expansion.
Outlook remains positive due to accelerating revenue and robust profitability, but high valuation multiples (P/E of 147.02) pose a risk if growth slows. Key opportunities include the $13.1 billion deal backlog and U.S. commercial segment growth, while risks involve competition and execution challenges in sustaining AI adoption momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
